Design and optimization of DPC-crosslinked HPβCD nanosponges for entrectinib oral delivery: formulation, characterization, and pharmacokinetic studies
Abstract Background In advanced or metastatic cancers characterized by specific genetic alterations, heightened growth and resistance to conventional therapies are common. Targeted treatments like entrectinib (ENT) precisely inhibit aberrant signaling pathways, potentially enhancing outcomes. The ob...
| Päätekijät: | , |
|---|---|
| Aineistotyyppi: | Artikkeli |
| Kieli: | English |
| Julkaistu: |
SpringerOpen
2024-08-01
|
| Sarja: | Future Journal of Pharmaceutical Sciences |
| Aiheet: | |
| Linkit: | https://doi.org/10.1186/s43094-024-00680-8 |